The Role of Chemokines During Lung Allograft Dysfunction
趋化因子在肺同种异体移植功能障碍中的作用
基本信息
- 批准号:7842039
- 负责人:
- 金额:$ 28.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AllograftingAlveolarBindingBiologicalBiological MarkersBiological ModelsBiological ProcessBiologyBrain DeathBronchiolitis ObliteransCXC ChemokinesChemotactic FactorsChronicDataDevelopmentDiffuseEventExtravasationFiberFunctional disorderG-Protein-Coupled ReceptorsHumanHypoxemiaIL8 geneIL8RB geneIncidenceInflammationInjuryInterleukin-8B ReceptorInterventionIschemiaLeadLigandsLungLung TransplantationLung diseasesMediatingModelingMorbidity - disease rateMusNatureNeutrophil InfiltrationPathogenesisPatientsPlayPreventionProcessRattusReperfusion InjuryReperfusion TherapyRisk FactorsRoleSeveritiesSourceSpecimenStagingSyndromeTestingTherapeuticTimeTissuesTransplantationVascular remodelingangiogenesisbasechemokineclinically relevantinsightlung allograftlung ischemiamortalityneutrophilnovelrepairedresearch studytherapeutic targettranslational study
项目摘要
DESCRIPTION (provided by applicant): Lung transplantation is considered to be a therapeutic option for patients with end-stage lung diseases. Unfortunately, due to the high incidence and severity of lung allograft dysfunction it is only a treatment and not a cure. Early lung allograft dysfunction (ischemia-reperfusion injury) is characterized by a neutrophil predominated inflammation. Mild ischemia-reperfusion injury occurs in up to 97% of lung transplantation recipients. The mortality rate for more severe episodes can be >40%. Importantly, early allograft dysfunction is a significant risk factor for the development of bronchiolitis obliterans syndrome (BOS). BOS is a chronic process with features of dysregulated repair and fibro-obliteration with granulation-like tissue formation within and around allograft airways. BOS is the main reason that the 5-year survival after lung transplantation is only 42%. The CXCR2/CXCR2 ligand biological axis is important in promoting neutrophil recruitment and in mediating angiogenesis. We hypothesized that CXCR2/CXCR2 ligand biological axis is critical to the continuum of early -> late (BOS) allograft dysfunction. To test this hypothesis, we will use a rat model system of clinically relevant cold ischemia-reperfusion injury, transition to a murine model of clinically relevant airway ischemia-reperfusion injury, which progresses to a murine model of BOS. Using these model systems we will dissect the bimodal biological function of CXCR2/CXCR2 ligands during ischemia-reperfusion (recruitment of neutrophils) and BOS (neutrophil-independent/angiogenesis-dependent). We will then perform exploratory translational studies on human specimens (i.e., BALF and TBBx) to demonstrate that the CXCR2/CXCR2 ligand biological axis indeed contributes to the continuum of early -> late allograft dysfunction. Moreover, we postulate that elevated levels of CXCR2 ligands present in early allograft dysfunction will predict the development of late (BOS) allograft dysfunction in patients. The persistent elevations of multiple CXCR2 ligands in BALF from patients with BOS will have significant angiogenic activity promoting fibro-obliteration during the pathogenesis of BOS. The aims in this proposal may lead to therapeutic targets for this biology and intervention to reduce the incidence of early (ischemiareperfusion injury) and late (BOS) lung allograft dysfunction.
描述(由申请人提供):肺移植被认为是末期肺部疾病患者的治疗选择。 不幸的是,由于肺同种异体功能障碍的发病率和严重程度高,这只是一种治疗而不是治愈方法。 早期同种异体移植功能障碍(缺血再灌注损伤)的特征是中性粒细胞主要炎症。轻度缺血再灌注损伤发生在多达97%的肺移植受者中。 更严重发作的死亡率> 40%。 重要的是,早期的同种异体功能障碍是开发细支气管炎综合征(BOS)的重要危险因素。 BOS是一个慢性过程,其修复和纤维融合功能失调的特征在同种异体移植气道内部和周围具有肉芽样组织形成。 BOS是肺移植后5年生存率仅为42%的主要原因。 CXCR2/CXCR2配体生物轴对促进中性粒细胞募集和介导血管生成很重要。 我们假设CXCR2/CXCR2配体生物轴对早期 - >晚(BOS)同种异体功能障碍至关重要。 为了检验这一假设,我们将使用临床上相关的冷缺血再灌注损伤的大鼠模型系统,过渡到临床相关气道缺血 - 再灌注损伤的鼠模型,该模型发展为BOS的鼠模型。 使用这些模型系统,我们将在缺血 - 再灌注(嗜中性粒细胞的募集)和BOS(中性粒细胞独立/血管生成依赖性)期间剖析CXCR2/CXCR2配体的双峰生物学功能。 然后,我们将对人类标本(即BALF和TBBX)进行探索性翻译研究,以证明CXCR2/CXCR2配体生物轴确实确实有助于早期 - >晚期同种异体功能障碍。 此外,我们假设早期同种异体移植功能障碍中存在的CXCR2配体水平升高将预测患者晚期(BOS)同种异体功能障碍的发展。 BAS患者BALF中多个CXCR2配体的持续升高将具有显着的血管生成活性,可促进BOS发病机理期间纤维融合。 该提案的目的可能导致该生物学和干预措施的治疗靶标,以减少早期(缺血性灌注损伤)和晚期(BOS)肺同种异体移植功能障碍的发生率。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis.
晚期特发性肺纤维化肺动脉高压筛查方法的验证。
- DOI:10.1378/chest.07-2488
- 发表时间:2008
- 期刊:
- 影响因子:9.6
- 作者:Zisman,DavidA;Karlamangla,ArunS;Kawut,StevenM;Shlobin,OksanaA;Saggar,Rajeev;Ross,DavidJ;Schwarz,MarvinI;Belperio,JohnA;Ardehali,Abbas;Lynch3rd,JosephP;Nathan,StevenD
- 通讯作者:Nathan,StevenD
Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.
- DOI:10.1111/j.1600-6143.2008.02338.x
- 发表时间:2008-09
- 期刊:
- 影响因子:0
- 作者:Saggar R;Ross DJ;Saggar R;Zisman DA;Gregson A;Lynch JP 3rd;Keane MP;Weigt SS;Ardehali A;Kubak B;Lai C;Elashoff D;Fishbein MC;Wallace WD;Belperio JA
- 通讯作者:Belperio JA
Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.
- DOI:10.1371/journal.pone.0011354
- 发表时间:2010-06-29
- 期刊:
- 影响因子:3.7
- 作者:Gregson AL;Hoji A;Palchevskiy V;Hu S;Weigt SS;Liao E;Derhovanessian A;Saggar R;Song S;Elashoff R;Yang OO;Belperio JA
- 通讯作者:Belperio JA
Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia.
特发性间质性肺炎的血清白蛋白浓度和等候名单死亡率。
- DOI:10.1378/chest.08-0754
- 发表时间:2009
- 期刊:
- 影响因子:9.6
- 作者:Zisman,DavidA;Kawut,StevenM;Lederer,DavidJ;Belperio,JohnA;Lynch3rd,JosephP;Schwarz,MarvinI;Tayek,JohnA;Reuben,DavidB;Karlamangla,ArunS
- 通讯作者:Karlamangla,ArunS
Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation.
曲前列环素逆转与特发性肺纤维化相关的肺动脉高压,作为单肺移植的桥梁。
- DOI:10.1016/j.healun.2009.05.017
- 发表时间:2009
- 期刊:
- 影响因子:0
- 作者:Saggar,Rajeev;Shapiro,ShelleyS;Ross,DavidJ;Fishbein,MichaelC;Zisman,DavidA;Lynch3rd,JosephP;Weigt,SamS;Ardehali,Abbas;Belperio,JohnA;Saggar,Rajan
- 通讯作者:Saggar,Rajan
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN A BELPERIO其他文献
JOHN A BELPERIO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN A BELPERIO', 18)}}的其他基金
Lung Transplant Clinical Trial Network (LT-CTN)
肺移植临床试验网络(LT-CTN)
- 批准号:
10469461 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Lung Transplant Clinical Trial Network (LT-CTN)
肺移植临床试验网络(LT-CTN)
- 批准号:
10636959 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis
模拟特发性肺纤维化的进行性纤维化体外模型的验证
- 批准号:
10027230 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis
模拟特发性肺纤维化的进行性纤维化体外模型的验证
- 批准号:
10350549 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis
模拟特发性肺纤维化的进行性纤维化体外模型的验证
- 批准号:
10542830 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Lung Transplant Clinical Trial Network (LT-CTN)
肺移植临床试验网络(LT-CTN)
- 批准号:
10282197 - 财政年份:2021
- 资助金额:
$ 28.85万 - 项目类别:
Epithelial Progenitor Cell Dysfunction in the Fibroproliferative Process of CLAD
CLAD 纤维增殖过程中的上皮祖细胞功能障碍
- 批准号:
10198013 - 财政年份:2012
- 资助金额:
$ 28.85万 - 项目类别:
Epithelial Progenitor Cell Dysfunction in the Fibroproliferative Process of CLAD
CLAD 纤维增殖过程中的上皮祖细胞功能障碍
- 批准号:
10450043 - 财政年份:2012
- 资助金额:
$ 28.85万 - 项目类别:
相似国自然基金
螺旋层状结构的矿化纤维素纳米晶材料的仿生构建及其促牙槽骨组织再生的机制研究
- 批准号:82301152
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
牙周膜细胞通过CXCL1-CXCR2轴调控巨噬细胞极化在正畸牙槽骨改建中的作用研究
- 批准号:82301115
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
长效抑炎修复材料通过诱导巨噬细胞极化促进牙槽骨再生研究
- 批准号:32301129
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Sparcl1调控Myh11+干细胞促进牙槽骨修复再生的机制研究
- 批准号:82370945
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
三维预血管化磷酸钙骨水泥牙槽骨组织工程支架的构建及三维共培养成血管相关机制的研究
- 批准号:82301117
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A novel bioengineering approach to restoring permanent periodontal inflammatory bone loss
一种恢复永久性牙周炎性骨质流失的新型生物工程方法
- 批准号:
10734465 - 财政年份:2023
- 资助金额:
$ 28.85万 - 项目类别:
Understanding Infantile Rhabdomyosarcoma Biology and Therapeutic Targets
了解婴儿横纹肌肉瘤生物学和治疗靶点
- 批准号:
10709542 - 财政年份:2022
- 资助金额:
$ 28.85万 - 项目类别:
Predicting the onset of chronic rejection in lung transplant recipients using hyperpolarized 129Xe imaging
使用超极化 129Xe 成像预测肺移植受者慢性排斥反应的发生
- 批准号:
10407561 - 财政年份:2020
- 资助金额:
$ 28.85万 - 项目类别:
Discoidin domain receptor 2, a novel regulator of bone regeneration
Discoidin 结构域受体 2,骨再生的新型调节剂
- 批准号:
9806949 - 财政年份:2019
- 资助金额:
$ 28.85万 - 项目类别:
Pathogenesis of lung injury mediated by lung-restricted antibodies
肺限制性抗体介导的肺损伤的发病机制
- 批准号:
10673371 - 财政年份:2019
- 资助金额:
$ 28.85万 - 项目类别: